Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genentech (NYSE:DNA) formerly known as (NYSE:GNE) -- Ignore unavailable to you. Want to Upgrade?

To: tnsaf who wrote (216)	11/19/2008 8:29:06 AM
From: tom pope	Respond to of 250

ALSO Avastin Analysis Finds Link to Blood-Clot Risk By THOMAS GRYTA A new analysis published in the Journal of the American Medical Association confirms that using Genentech Inc.'s cancer drug Avastin increases the risk of patients developing blood clots. Avastin, which had 2007 sales of $2.3 billion, is approved to treat advanced breast, colon and lung cancers. Venous thromboembolism, or blood clots forming in the vein, is already listed on Avastin's label as a reported adverse event. Previously, Avastin was only "associated" with the risk of the clotting, and this analysis shows a clearer connection, said Shenhong Wu, an assistant professor of medical oncology at Stony Brook University Medical Center, in Stony Brook, N.Y., and one of the authors of the analysis. Importantly, the analysis notes that the increased risk of venous thromboembolism may be secondary to a patient's prolonged survival, which Avastin has shown in advanced lung and colorectal cancer. As a result, the analysis is not seen changing how doctors use the drug, but may result in some changes to the label by Genentech, of South San Francisco, Calif.

To: tnsaf who wrote (216)	2/20/2009 8:23:32 AM
From: nigel bates	Read Replies (1) \| Respond to of 250

FDA issues warning for Genentech drug Raptiva Silicon Valley / San Jose Business Journal - by Ron Leuty 20th Feb At least two patients using the Genentech Inc. psoriasis drug Raptiva have died from a rare brain infection progressive multifocal leukoencephalopathy, or PML, the Food and Drug Administration said. The FDA’s public health advisory on Raptiva comes four months after the agency revised labeling for the drug that called attention to the risk of infections like PML. At that time, South San Francisco-based Genentech (NYSE:DNA) was told to develop a strategy to ensure that patients receive risk information about Raptiva. European regulators recommended suspending Raptiva sales, the news agency Bloomberg reported. Merck KGaA of Germany sells Raptiva outside the United States. PML is a rare, progressive neurologic disease caused by a virus that affects the central nervous system. It typically occurs in people whose immune systems have been severely weakened. There is no known treatment. Raptiva, or efalizumab, works by affecting T-cells in the immune system. The effects also decrease the function of the immune system and increase susceptibility to infections. Raptiva sales last year totaled $108 million, only 1 percent of Genentech’s total U.S. product sales of $9.5 billion. Three of four reported PML cases have been confirmed. Two of the patients with confirmed PML and one patient with possible PML died. All were 47 to 73 years old, were treated with Raptiva continuously for more than three years and were not receive other immune system-suppressing treatments while taking the drug. “The FDA is reviewing this latest information,” the agency said on its web site. “The agency will take appropriate steps to ensure that the risks of Raptiva do not outweigh its benefits, that patients prescribed Raptiva are clearly informed of the signs and symptoms of PML, and that health-care professionals carefully monitor patients for the possible development of PML.” Raptiva was approved in October 2003 to treat chronic moderate to severe plaque psoriasis. Raptiva treated 2,764 patients at the time of its approval — but only 218 for more than one year — and there were no cases of PML at the time of its approval. The label warning last fall came after one case was reported. The FDA said long, continuous use of Raptiva may increase the risk of PML.